CAR19T2 T cells
/ Zhaotai InVivo Biomedicine
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
March 18, 2024
CAR19T2: CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma
(clinicaltrials.gov)
- P1/2 | N=0 | Withdrawn | Sponsor: Zhujiang Hospital | N=70 ➔ 0 | Not yet recruiting ➔ Withdrawn
CAR T-Cell Therapy • Enrollment change • Trial withdrawal • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
November 14, 2022
CAR19T2: CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/Lymphoma
(clinicaltrials.gov)
- P1/2 | N=70 | Not yet recruiting | Sponsor: Zhujiang Hospital
CAR T-Cell Therapy • New P1/2 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19
1 to 2
Of
2
Go to page
1